News >

Neratinib/T-DM1 Combo Shows Promise in HER2-Positive Breast Cancer

Jason Harris
Published: Monday, Jun 18, 2018

Jame Abraham, MD

Jame Abraham, MD

The combination of neratinib (Nerlynx) and T-DM1 (ado-trastuzumab emtansine; Kadcyla) induced an overall response rate of 60% in previously-treated women with HER2-positive metastatic breast cancer, according to results from the phase Ib NSABP FB-10 study presented at the 2018 ASCO Annual Meeting.1

Investigators will continue to evaluate the efficacy of neratinib/TDM-1 in the phase II portion of the study. The combination of budesonide and loperamide—which has been shown to reduce the incidence of grade 3 diarrhea—will also be evaluated.

References

  1. Abraham J, Puhalla S, Sikov WM, et al. NSABP FB-10: phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DM1) with neratinib (N) in women with metastatic HER2+ breast cancer (MBC). J Clin Oncol. 36, 2018 (suppl; abstr 1027).
  2. Martin M, Holmes FA, Ejertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x